Partners & Customers
10About Apricus Biosciences
Apricus Biosciences is a pharmaceutical company that has leveraged the flexibility of clinically-validated NexACT drug delivery technology to enable multi-route administration of new and improved compound. In addition, the company is seeking to monetize its existing product pipeline, including its first product, Vitaros, approved in Canada for the treatment of erectile dysfunction and compounds in development from pre-clinical through Phase III, focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.

Want to inform investors similar to Apricus Biosciences about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Apricus Biosciences News
Jan 31, 2023
| Apricus Biosciences, Inc., Bayer AG News Provided By Share This Article Infertility Drugs and Devices Market Analysis The global infertility drugs and devices market is estimated to account for US$ 9,702.4 Mn in terms of value by the end of 2030. BURLINGAME, CALIFORNIA, UNITED STATES, January 31, 2023 / EINPresswire.com / -- The market study on Infertility Drugs and Devices Market examines the topic in respect to a number of industry elements, including market size, status, trends, and prediction. Additionally, the report offers a brief synopsis of rival companies as well as particular growth opportunities with significant market drivers. The research includes a thorough evaluation of the Infertility Drugs and Devices market, split by companies, regions, types, and applications. Edition : 2023 Scope of Infertility Drugs and Devices For 2023: Infertility Drugs and Devices Market research assesses the rate of growth and market value based on market dynamics and growth generating variables. Complete understanding is based on the most recent industry news, prospects, and trends. The research includes a thorough market analysis and vendor landscape, as well as a SWOT analysis of the top vendors. For In depth Information Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4122 ** Note – This report sample includes: ▪️ Scope For 2023 ▪️ Table of Contents (Scope covered as a part of the study) ▪️ Top players in the market ▪️ Research framework (structure of the report) ▪️ Research methodology adopted by Coherent Market Insights Major companies in Infertility Drugs and Devices Market are: ✤ Apricus Biosciences Inc. ✤ Dr. Reddys Laboratories Ltd → Additionally, this report discusses the major factors influencing market growth as well as the possibilities, risks, and challenges that the industry as a whole and key competitors in particular face. It also looks at important new trends and how they might affect both present and future growth. → The in-depth review of the global Infertility Drugs and Devices market’s new developments, controversial trends, market pilots already in place, challenges, norms, and technical domain. This report also splits the market by region: ➸ North America (United States, Canada and Mexico) ➸ Europe (Germany, UK, France, Italy, Russia and Turkey, Rest of Europe) ➸ Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam Rest of Asia) ➸ South America (Brazil, Argentina, Columbia, Reset of South America) ➸ Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and Rest of South Africa & Middle East) What makes the information worth buying? • A comprehensive and in-depth overview of the global Infertility Drugs and Devices industry in exchange, use, and geographical area sectors is provided. • This research looks at the industry rewards and constraints that influence industry growth. • Developing business strategies and aspects to aid in an emerging market. • Examining free markets and developing appropriate strategies. Limited Period Offer | Buy Now, Get Up to 45% Off on Research Report @ https://www.coherentmarketinsights.com/promo/buynow/4122 Global Infertility Drugs and Devices Market 2022 Key Insights: – Examine the current state of the Infertility Drugs and Devices market and its future prospects in relation to production, Infertility Drugs and Devices pricing structure, consumption, and previous experience. – The research identifies the many segments and sub-segments that make up the structure of the Infertility Drugs and Devices market. – Market historical information from 2016 to 2022 and forecast through 2030. Market breakdown information by company, products, end-users, and key countries. – Analysis of the Infertility Drugs and Devices market’s growth patterns, prospects for the future, and contribution to the entire keyword market. – Report on the Global Infertility Drugs and Devices Market 2022 examines competitive developments such as contracts, the introduction of new products, and Infertility Drugs and Devices Market acquisition. – To characterise sales volume, Infertility Drugs and Devices revenue, growth potential, drivers, SWOT analysis, and Infertility Drugs and Devices development plans in the upcoming years, the research report targets the major international Infertility Drugs and Devices players. Table of Contents: Infertility Drugs and Devices Market Part 1: Overview of Infertility Drugs and Devices Market Part 2: Infertility Drugs and Devices Carts: Global Market Status and Forecast by Regions Part 3: Global Market Status and Forecast by Types Part 4: Global Market Status and Forecast by Downstream Industry Part 5: Market Driving Factor Analysis Part 6: Market Competition Status by Major Manufacturers Part 7: Major Manufacturers Introduction and Market Data Part 8: Upstream and Downstream Market Analysis Part 9: Cost and Gross Margin Analysis Part 10: Marketing Status Analysis Part 11: Market Report Conclusion Part 12: Infertility Drugs and Devices: Research Methodology and Reference About Coherent Market Insights Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Mr. Shah +1 206-701-6702
Apricus Biosciences Acquisitions
2 Acquisitions
Apricus Biosciences acquired 2 companies. Their latest acquisition was Seelos Therapeutics on July 30, 2018.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
7/30/2018 | Reverse Merger | 3 | ||||
12/30/2011 |
Date | 7/30/2018 | 12/30/2011 |
---|---|---|
Investment Stage | ||
Companies | ||
Valuation | ||
Total Funding | ||
Note | Reverse Merger | |
Sources | 3 |
Apricus Biosciences Partners & Customers
10 Partners and customers
Apricus Biosciences has 10 strategic partners and customers. Apricus Biosciences recently partnered with Ferring Pharmaceuticals on March 3, 2017.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
3/10/2017 | Partner | Switzerland | Saint-Prex , Switzerland -- 09 March 2017 -- Ferring Pharmaceuticals today announced an agreement with Apricus Biosciences , Inc. , granting Ferring Pharmaceuticals global assets and rights , excluding the U.S. , related to Apricus Biosciences , Inc. ' Vitaros ® . | 1 | |
8/4/2016 | Licensee | Switzerland | , if any ; Apricus Biosciences , Inc. ' plans for life-cycle development programs for Vitaros ; Apricus Biosciences , Inc. ' development and partnering plans for RayVa ; Apricus Biosciences , Inc. ' plans to pursue out-licensing opportunities for Vitaros in . | 6 | |
4/6/2016 | Partner | United States | Rationalize the Development Pipeline. , if any ; Apricus Biosciences , Inc. ' plans for life-cycle development programs for Vitaros ; Apricus Biosciences , Inc. ' development and partnering plans for RayVa ; and Apricus Biosciences , Inc. ' plans to streamline the Company , reduce operating expenses and achieve profitability . | 1 | |
10/1/2015 | Partner | ||||
8/8/2014 | Partner |
Date | 3/10/2017 | 8/4/2016 | 4/6/2016 | 10/1/2015 | 8/8/2014 |
---|---|---|---|---|---|
Type | Partner | Licensee | Partner | Partner | Partner |
Business Partner | |||||
Country | Switzerland | Switzerland | United States | ||
News Snippet | Saint-Prex , Switzerland -- 09 March 2017 -- Ferring Pharmaceuticals today announced an agreement with Apricus Biosciences , Inc. , granting Ferring Pharmaceuticals global assets and rights , excluding the U.S. , related to Apricus Biosciences , Inc. ' Vitaros ® . | , if any ; Apricus Biosciences , Inc. ' plans for life-cycle development programs for Vitaros ; Apricus Biosciences , Inc. ' development and partnering plans for RayVa ; Apricus Biosciences , Inc. ' plans to pursue out-licensing opportunities for Vitaros in . | Rationalize the Development Pipeline. , if any ; Apricus Biosciences , Inc. ' plans for life-cycle development programs for Vitaros ; Apricus Biosciences , Inc. ' development and partnering plans for RayVa ; and Apricus Biosciences , Inc. ' plans to streamline the Company , reduce operating expenses and achieve profitability . | ||
Sources | 1 | 6 | 1 |
Apricus Biosciences Team
2 Team Members
Apricus Biosciences has 2 team members, including former Chief Financial Officer, Senior Vice President, Steve Martin.
Name | Work History | Title | Status |
---|---|---|---|
Steve Martin | Chief Financial Officer, Senior Vice President | Former | |
Name | Steve Martin | |
---|---|---|
Work History | ||
Title | Chief Financial Officer, Senior Vice President | |
Status | Former |